Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year

BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year

July 30, 2026Posted inBiotechnology

BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.

Post navigation

Previous Post
non-invasive-biomarkers-for-early-oral-cancer-detection-through-multiomics-approach Non-invasive biomarkers for early oral cancer detection through multiomics approach
Next Post
Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate latigo-reports-positive-phase-iib-data-for-non-opioid-acute-pain-candidate

Recent Posts

  • Activity-regulated myelin pathway drives organelle transport in oligodendrocytes
  • CD8⁺ TRM–chemokine axis drives liver fibrosis, reveals biomarkers in chronic Clonorchis infection
  • Paracetamol Use and Bronchopulmonary Dysplasia Risk in Extremely Preterm Infants
  • Community Partnership Measures Soil Lead in Urban Home Dust, Pre-/Post-1978
  • Global Markets React to New Shark Finning Regulations

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top